Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers von Quintela-Fandino, M., Manso Sànchez, L.M., Holgado Martín, E., Moreno, M.C., Morales Murillo, S., Bermejo De Las Heras, B., Malon Gimenez, D., Colomer Bosch, R., Gonzalez Cortijo, L., Hornedo, J., Mouron, S., Muñoz, M., Escudero, S., Blanco, R., Mañes, S.

Volltext

38P Impact of 1-year COVID-19 pandemic in patients with ovarian carcinoma treated with chemotherapy based on a global data network von Manso Sanchez, L.M., Madariaga Urrutia, A., Hernández-Ibarburu, G., Sanchez Bayona, R., Tolosa Ortega, P., Lema Roso, L., Alva, M., Modrego, A., Serrano, P., Paz-Ares, L.

Volltext

6P The oncolytic virus pelareorep primes the tumor microenvironment for checkpoint blockade therapy in early breast cancer patients: Results from AWARE-1 study von Gavila Gregori, J., Loghmani, H., Manso Sanchez, L.M., Gonzalez, A., Pare Brunet, L., Salvador, F., Pascual, T., Gonzalez-Farre, B., Juan, M., Prat, A., Heineman, T.C.

Volltext

761P A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular class... von Piulats Rodriguez, J.M., Palacio Vazquez, I., Alarcon, J.D., Gatius, S., Marin Jimenez, J.A., Gil Martín, M., Márquez Aragonés, A., Santacana, M., Manso Sanchez, L.M., Hernando Polo, S., Ruiz, N., Matias-Guiu, X., Romeo Marin, M., Navarro Garces, V., Barbarroja, P.

Volltext

748P Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma von Oaknin, A., Drescher, C., Banda, K., Duska, L., Ribrag, V., Tewari, A., Lakhani, N.J., Eberst, L., Harvey, R.D., Sanchez, L.M. Manso, Lorusso, D., Kindler, H., Walter, H.S., Illescas, D.G., Pons-Tostivint, E., Thakur, A.G., Kann, L., Reddy, A., Faulhaber, N., González-Martín, A.

Volltext

757P Sustained long-term responders to niraparib maintenance in recurrent platinum-sensitive high-grade ovarian cancer (PSROC): A subanalysis of the GEICO-88R study von Cueva Banuelos, J.F., Palacio Vazquez, I., Maximiano Alonso, C., Estevez Garcia, P., Manso Sanchez, L.M., Constenla Figueiras, M., Garcia Garcia, Y., Cros Costa, S., Salvador Coloma, C., Santaballa Bertran, A., Cassinello, J.G., Corbellas Aparicio, M., Hernando Polo, S., De Juan Ferre, A., Herrero Ibañez, A., Guerra Alia, E.M., Fuentes Pradera, J., Iriarte Moncho, M.E., González-Martín, A.

Volltext

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC) von Goetz, M.P., Toi, M., Huober, J., Sohn, J., Tredan, O., Park, I.H., Campone, M., Chen, S.C., Sanchez, L.M. Manso, Paluch-Shimon, S., van Hal, G., Shahir, A., Iwata, H., Johnston, S.

Volltext

288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or met... von Fujiwara, K., Slomovitz, B.M., Gonzalez Martin, A., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., Vergote, I.B.

Volltext

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or meta... von Vergote, I.B., Gonzalez Martin, A., Fujiwara, K., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., Van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., Slomovitz, B.M.

Volltext

95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study von Pascual, T., Bermejo De Las Heras, B., Martinez, N., Oliveira, M., Pernas Simon, S., Lopez Lopez, R., Ruiz Cabrero, I., Alarcon, J.D., Martinez De Dueñas, E., Malon Gimenez, D., Gonzalez Cao, M., Manso Sanchez, L.M., Morales Murillo, S., Lopez de Ceballos, H., Cortés, J., Llombart Cussac, A., Prat, A.

Volltext

357TiP SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast canc... von Cortés, J., Diab, S., Basho, R.K., Oliveira, M., Pluard, T., Alemany, C., Brown-Glaberman, U., Meisel, J., Boni, V., Sinha, R., Estevez, L. García, Ettl, J., Kuemmel, S., Sanchez, L.M. Manso, Moon, Y.W., Vazquez, R. Villanueva, Wuerstlein, R., Wang, Y., Wang, Z., Han, H.

Volltext

234P Real-world treatment patterns and outcomes of patients receiving palbociclib plus endocrine therapy in Spain: Subgroup analysis based on age, sites and number of metastatic lo... von Anton, F. Moreno, Bellet-Ezquerra, M., Sanchez, L.M. Manso, Carrasco, F. Henao, Torres, A. Anton, Morales, S., Ortega, P. Tolosa, Gil, V.L. Obadia, Sampedro, T., Conejero, R. Andrés, Calvo-Martinez, L., Galve-Calvo, E., López, R., Ayala de la Pena, F., Lopez-Tarruella Cobo, S., Hernando Fernandez, B.A., Ruiz, L. Boronat, Cardenas, T. Martos, Chacon, J.I., Jañez, N. Martinez

Volltext

Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced... von Sánchez, L.M. Manso, Antón, F. Moreno, Perón, Y. Izarzugaza, De Mingorance, J. Ilgado, Borrega, P., González, M.J. Echarri, Martínez, N., González, A. López, Olier, C., García, A. Ballesteros, Chacón, I., Ciruelos, E., García-Sáenz, J.A., Paz-Ares, L.

Volltext

InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator's choice of chemotherapy in 2L or 3L recurrent or metastati... von Fujiwara, K, Slomovitz, B.M, Gonzalez Martin, A, Kalbacher, E, Bagameri, A, Ghamande, S, Lee, J.-Y, Banerjee, S, Maluf, F.C, Lorusso, D, Yonemori, K, van Nieuwenhuysen, E, Manso Sanchez, L.M, Woelber, L, Westermann, A.M, Covens, A, Whalley, E, Teng, M.S.L, Soumaoro, I, Vergote, I.B

Volltext

880TiP Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: A... von Oaknin, A., Iglesias, M., Alarcon, J.D., Villacampa Javierre, G., Garcia, L. Gaba, Santaballa, A., Manso, L.M., Romero, I., Barretina Ginesta, M.P., Churruca, C., García, Y., Sanchez, A.B., Marquina, G., Pardo, B., Redondo, A., Rubio, M.J., González Martín, A.

Volltext